IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Summary

IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.

Timeline

Start

2019-07-04

Primary completion

2024-06

Completion

2024-07

Publications

• Frazer LC, Orgel KA, Good M. Dysbiotic Microbiota in Necrotizing Enterocolitis: Insights into Pathogenesis, Treatment, and Prevention. Gastroenterol Clin North Am. 2025 Jun;54(2):415-427. doi: 10.1016/j.gtc.2024.11.001. Epub 2025 Jan 24.

Drugs

Indications